Get the Stockscreener App
5.19
0.57%
-0.03
After Hours:
5.15
-0.04
-0.77%
Jasper Therapeutics Inc stock is traded at $5.19, with a volume of 221.06K.
It is down -0.57% in the last 24 hours and down -16.96% over the past month.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
See More
Previous Close:
$5.22
Open:
$5.23
24h Volume:
221.06K
Relative Volume:
0.44
Market Cap:
$77.96M
Revenue:
-
Net Income/Loss:
$-64.47M
P/E Ratio:
-0.8391
EPS:
-6.1852
Net Cash Flow:
$-52.33M
1W Performance:
-3.71%
1M Performance:
-16.96%
6M Performance:
-78.29%
1Y Performance:
-80.22%
1-Day Range:
$5.1468
$5.4281
1-Week Range:
$5.12
$5.71
52-Week Range:
$4.55
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Name
Jasper Therapeutics Inc
Sector
Industry
Phone
(650) 549-1400
Address
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
5.19 | 77.96M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | UBS | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Sep-09-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-08-24 | Initiated | BTIG Research | Buy |
| Jun-27-24 | Initiated | Stifel | Buy |
| May-06-24 | Initiated | H.C. Wainwright | Buy |
| Apr-03-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-18-24 | Initiated | TD Cowen | Outperform |
| Aug-11-23 | Initiated | CapitalOne | Overweight |
| Feb-28-22 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Credit Suisse | Outperform |
| Oct-21-21 | Initiated | William Blair | Outperform |
| Oct-20-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-13-21 | Initiated | Oppenheimer | Outperform |
View All
Jasper Therapeutics Inc Stock (JSPR) Latest News
Jasper Therapeutics inks new sales agreement, ends previous deal - Investing.com India
Jasper Therapeutics Signs New Sales Agreement with Jefferies - TipRanks
Jasper Therapeutics terminates Cantor sales agreement -March 19, 2025 at 04:53 pm EDT - Marketscreener.com
Jasper Therapeutics files for mixed shelf offering of up to $300 mln -March 19, 2025 at 04:17 pm EDT - Marketscreener.com
(JSPR) On The My Stocks Page - Stock Traders Daily
Jasper Therapeutics’ (JSPR) Buy Rating Reiterated at HC Wainwright - Defense World
Promising Innovations in Chronic Urticaria Treatment Drive Buy Rating for Jasper Therapeutics - TipRanks
FY2025 EPS Estimates for JSPR Raised by Cantor Fitzgerald - Defense World
Oppenheimer maintains $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Stifel maintains Buy rating, $80 target on Jasper Therapeutics stock By Investing.com - Investing.com Canada
Positive Outlook for Jasper Therapeutics: Buy Rating Affirmed on Promising BEACON Study Data and Strategic Milestones - TipRanks
Jasper Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Equities Analysts Set Expectations for JSPR Q1 Earnings - Defense World
Jasper Therapeutics presents updated data from Phase 1b/2a BEACON study - MSN
JSPRJasper Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Jasper Therapeutics Presents Updated Clinical Data on Briquilimab at AAAAI 2025 Annual Meeting - Nasdaq
Jasper Therapeutics Presents Clinical and Preclinical - GlobeNewswire
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - Yahoo Finance UK
Can Jasper Therapeutics' Briquilimab Transform Chronic Urticaria Treatment? New Clinical Data Revealed - StockTitan
Promising Outlook for Jasper Therapeutics: Buy Rating Backed by Briquilimab’s Clinical Progress and Financial Stability - TipRanks
Jasper Therapeutics Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Jasper Therapeutics, Inc. SEC 10-K Report - TradingView
Jasper Therapeutics to present briquilimab study at AAD Meeting - Investing.com India
Jasper Therapeutics to present briquilimab study at AAD Meeting By Investing.com - Investing.com South Africa
Jasper Therapeutics Announces Late-Breaking Briquilimab - GlobeNewswire
Can Jasper's Briquilimab Data for Chronic Urticaria Transform Treatment Outcomes? - StockTitan
Jasper Therapeutics Reports Promising Clinical Progress - TipRanks
Jasper Therapeutics: Strategic Advancements and Promising Clinical Efficacy Drive Buy Rating - TipRanks
Promising Data from Jasper Therapeutics’ BEACON and SPOTLIGHT Studies Justify Buy Rating for Briquilimab - TipRanks
Jasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23) - TipRanks
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings To Watch: Life Time (LTH) Reports Q4 Results Tomorrow - The Globe and Mail
Jasper Therapeutics to Present at Upcoming March Investor Conferences - The Manila Times
Jasper Therapeutics Sets March Conference Circuit to Showcase Mast Cell Disease Breakthroughs - StockTitan
Jasper Therapeutics’ SWOT analysis: briquilimab’s potential reshapes CSU stock outlook - Investing.com
Jasper Therapeutics' SWOT analysis: briquilimab's potential reshapes CSU stock outlook - Investing.com India
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $64.44 Consensus PT from Analysts - Defense World
Learn to Evaluate (JSPR) using the Charts - Stock Traders Daily
Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
What To Expect From RE/MAX’s (RMAX) Q4 Earnings - The Globe and Mail
Jasper Therapeutics stock holds $70 target at JMP Securities By Investing.com - Investing.com Canada
Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Down 11.1% in January - Defense World
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at UBS Group - MarketBeat
UBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy Recommendation - Nasdaq
JSPR stock touches 52-week low at $5.22 amid market challenges - Investing.com Nigeria
Objective long/short (JSPR) Report - Stock Traders Daily
Jasper Therapeutics Announces Briquilimab Presentations at - GlobeNewswire
Jasper Therapeutics Announces Presentations of Briquilimab Data at AAAAI 2025 Annual Meeting - Nasdaq
JSPR’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - The InvestChronicle
Selling Buzz: Jasper Therapeutics Inc [JSPR] Chief Operating Officer Mahal Jeetinder Singh sells 900 shares of the company – Knox Daily - Knox Daily
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference - GlobeNewswire
Jasper Therapeutics Inc Stock (JSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):